Genetic modifications of Ad11 for tumor-selectivity and evaluation of tumor-selective replication.

<p><b>(A)</b> Genome sequence alignment of wild-type Ad5, wild-type Ad11, and modified Ad11 in the promoter region of the E1A gene. The endogenous promoter region of wild-type Ad11 was replaced with E2F1 promoter in the modified Ad11, resulting in its tumor-selective replication. &...

Cijeli opis

Spremljeno u:

Bibliografski detalji
Glavni autor:	Masahisa Hemmi (21601907) (author)
Daljnji autori:	Midori Yamashita (21601910) (author), Yoshiko Shimizu (171960) (author), Shinsuke Nakao (52048) (author)
Izdano:	2025
Teme:	Medicine Cell Biology Molecular Biology Pharmacology Biotechnology Ecology Immunology Cancer Mental Health Hematology Infectious Diseases Virology Chemical Sciences not elsewhere classified shown clinical benefit promising therapeutic approach minimum binding affinity ad11 antibody clones killing cancer cells cancer cells inhibit binding cancer types cancer treatment vec ), unique modality talimogene laherparepvec several limitations selectively replicate prevent use oncolytic viruses natural receptor multifaceted mechanisms intravenous administration intratumoral administration human erythrocytes ensuring safe class agent broader range advanced melanoma ad11 fibers
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Genetic modifications of Ad11 for tumor-selectivity and evaluation of tumor-selective replication.

Slični predmeti